trial · primary record
AB-2100
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 37 |
| Primary completion | 2028-06-30 |
| Primary endpoint | Phase 1 (Dose escalation): incidence of adverse events |
| Registry ID | NCT06245915 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:15.434Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06245915
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.